Option Circle | $3,000,000 | (Mar 12, 2026)
Standard Kernel Co. | $20,000,000 | (Mar 12, 2026)
Chowbus | $81,000,000 | (Mar 12, 2026)
GelMEDIX
United States
- Cambridge, MA
- 18/02/2026
- Seed
- $13,000,000
GelMEDIX is a biotechnology company developing regenerative medicines committed to combatting vision loss with our groundbreaking biomaterials platform.
Our lead program is focused on preserving vision for patients suffering from Geographic Atrophy (GA), the leading cause of blindness in adults over 60. With no approved therapies to maintain vision, patients continue to lose their independence. Regenerative medicine, specifically retinal pigment epithelial (RPE) cell therapy, has the potential to transform care by regenerating lost retina and preserving vital structures required for vision.
Our iPSC-derived RPE cell therapy utilizes an advanced hydrogel scaffold, demonstrating remarkable visual preservation for up to 92 days in preclinical studies, all while eliminating the risks that have plagued previous therapies. Join us on this exciting journey toward restoring sight!
- Industry Biotechnology Research
- Website https://www.gelmedix.com/
- LinkedIn https://www.linkedin.com/company/gelmedix/
Related People
Max CotlerFounder
United States -
Cambridge, Massachusetts
With over six years of experience in biotechnology and medical engineering, Max is the Chief Executive Officer at GelMEDIX, an early-stage ocular cell therapy company that is engineering the next generation of therapies to restore vision.
zymtrace | $12,200,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)
Ernesta Inc. | $20,000,000 | (Mar 12, 2026)
Translucent AI | $27,000,000 | (Mar 12, 2026)
Xscape Photonics Inc | $37,000,000 | (Mar 12, 2026)
Swarm Aero | $35,000,000 | (Mar 12, 2026)
anchr | $5,800,000 | (Mar 12, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)